98 results
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
25 Apr 24
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
6:46am
Disease and entry into the Innovative Licensing and Access Pathway (ILAP) by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). SAGE … to support our goals; early positive signs from launch or from our engagements with healthcare professionals, patients and payors related to ZURZUVAE
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
17 Apr 24
Regulation FD Disclosure
6:35am
Greene, Chief Executive Officer at Sage Therapeutics. “We are thankful for the patients and healthcare professionals who participated in this research
8-K
EX-99.1
olqsur08
14 Feb 24
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
ceqn69sen3jhl5be
8 Jan 24
Departure of Directors or Certain Officers
6:45am
8-K
EX-99.2
742gurrz927 m4
8 Jan 24
Departure of Directors or Certain Officers
6:45am
8-K
EX-1.1
5joqt9 xmu24
7 Nov 23
Entry into a Material Definitive Agreement
7:39am
424B5
0peexq934i7y6w a0xy
7 Nov 23
Prospectus supplement for primary offering
7:29am
8-K
EX-99.1
15lmxqmzpp6kxb
7 Nov 23
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:46am
8-K
EX-99.1
ib3qg9d
7 Aug 23
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.1
kpkwx moj2dn01
2 May 23
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.1
aw5r6ear8i 73u1q
8 Nov 22
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
6:45am